medigraphic.com

2016, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2016; 54 (6)

Dynamic, long-term, and institutional psychotherapy to treat persistent depressive disorders

Garibay J

Language: Spanish
References: 36
Page: 714-725
PDF size: 343.17 Kb.


ABSTRACT

Background: Major depression is a public health problem that threatens to become the second leading cause of disability in the world. In this study we show the results obtained once we applied a psychodynamic psychotherapeutic and long-term process in patients with major depressive disorder, attending a public health institution (PHI).
Methods: From a list of female volunteers, we randomly selected 30 patients who met the diagnostic criteria of major depression. They were divided into 5 groups, with 6 members each. Due to the high percentage of early desertions, we had to select from the very same list other 28 depressed women. In this framework there was not a full-time psychotherapist organizing and directing the psychotherapeutic process; the patients themselves were the ones who assumed such functions.
Results: From the group of 58 patients, 26 completed the program scheduled. From this subgroup, 20 were responders and the rest, the other 6, non-responders. After the end of the psychotherapeutic process, the latter kept ingesting psychotropic drugs.
Conclusions: If we correct the mistakes made in this first opportunity and we implement new strategies, the psychotherapeutic process can be transformed into a more institutional tool. Psychotherapy directed only to the cases difficult to solve is significantly effective, safe, cheap, and it may achieve a wide coverage.


REFERENCES

  1. Wagner FA, González-Forteza C, Sánchez-García S, García-Peña C, Gallo JJ. Enfocando la depresión como problema de salud pública en México. Salud Ment. 2012;35:3-11.

  2. Cantero Tellez EA, Ramirez-Paéz JA. Factores psicosociales y depresión laboral: una revisión. Rev Med Inst Mex Seguro Soc. 2009; 47(6):627-36.

  3. American Psychiatric Association. Manual Diagnóstico y Estadístico de los Trastornos Mentales (DSM-IV). Primera edición (en español). Barcelona, España: Masson; 1995. p. 326.

  4. Yoshimura R, Kishi T, Hori H, Ikenouchi-Sugita A, Katsuki A, Umene-Nakano W, et al. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):355-7. doi: 10.1016/j.pnpbp.2012.07.008.

  5. Muñoz RF. La depresión de nuestros pueblos (conferencia magistral). Salud Ment. 2005;28(4):1-9.

  6. Tamayo JM, Rosales-Barrera JI, Villaseñor-Bayardo SJ, Rojas-Malpica C. Definición e impacto de las depresiones resistentes/refractarias al tratamiento. Salud Ment. 2011;34(3):247-55.

  7. Galván P, Fernández E, Fonseca J. Síntomas residuales en el anciano con depresión. Semergen. 2012;38(5):285-91.

  8. Phillips JL, Batten LA, Aldosary F, Tremblay P, Blier P. Brain-volume increase with sustained remission in patients with treatment-resistant unipolar depression. J Clin Psychiatry. 2012 May;73(5):625-31. doi: 10.4088/JCP.11m06865.

  9. Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA. How should residual symptoms be defined in depressed patients who have remitted? Comprehensive Psychiatry. 2013, 54(2):91-6.

  10. Bennabi D, Aouizerate B, El-Hage W, Doumy O, Moliere F, Courtet P, et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 2015 Jan 15;171:137-41. doi: 10.1016/j.jad.2014.09.020.

  11. Tripp A, Oh H, Guilloux JP, Martinowich K, Lewis DA, Sibille E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry. 2012 Nov;169(11):1194-202. doi: 10.1176/appi. ajp.2012.12020248.

  12. Yao S, Liu M, Liu J, Hu Z, Yi J, Huang R. Inhibition dysfunction in depression: event-related potentials during negative affective priming. Psychiatry Res. 2010 May 30;182(2):172-9. doi: 10.1016/j. pscychresns.2010.01.010.

  13. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest. 2009 Apr 1;119(4):717-25. doi: 10.1172/JCI38454.

  14. Myint AM, Kim YK. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2014;48:304-13. DOI: 10.1016/j. pnpbp.2013.08.008

  15. Cuijpers P, van Straten A, Bohlmeijer E, Hollon SD, Andersson G. The effects of psychotherapy for adult depression are overestimated: a metaanalysis of study quality and effect size. Psychol Med. 2010 Feb;40(2):211-23. doi: 10.1017/ S0033291709006114.

  16. López J, López MA, Vargas BE, Villamil V. Estudio doble ciego con antidepresivo, psicoterapia breve y placebo en pacientes con depresión leve a moderada. Salud Ment. 2004;27(5):53-61. Disponible en http://www.redalyc.org/pdf/582/58252707.pdf

  17. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010 Jan;40(1):41-50. doi: 10.1017/ S0033291709006011.

  18. Bellón JÁ, Moreno-Küstner B, Torres-González F, Montón-Franco C, Gil de Gómez-Barragán MJ, Sánchez-Celaya M, et al. Predicting the onset and persistence of episodes of depression in primary health care. The predictD-Spain study: Methodology BMC Public Health. 2008;8:256. DOI: 10.1186/1471-2458-8-256.

  19. Cooper AA, Conklin LR. Dropout from individual psychotherapy for major depression: A meta-analysis of randomized clinical trials. Clin Psychol Rev. 2015 Aug;40:57-65. doi: 10.1016/j.cpr.2015.05.001.

  20. Knekt P, Lindfors O, Laaksonen MA, Renlund C, Haaramo P, Härkänen T, et al. Quasi-experimental study on the effectiveness of psychoanalysis, longterm and short-term psychotherapy on psychiatric symptoms, work ability and functional capacity during a 5-year follow-up. J Affect Disord. 2011 Jul;132(1-2):37-47. doi: 10.1016/j.jad.2011.01.014.

  21. Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. This version published: 2015; Review content assessed as up-to-date: April 12, 2013. Disponible en http://onlinelibrary.wiley. com/doi/10.1002/14651858.CD004044.pub4/full

  22. Insa-Gómez FJ, Elvira-Peña L. Depresión secundaria a tumor cerebral. Psiq Biol. 2005;12(2):79-87.

  23. Fonagy P, Roth A, Higgitt A. The outcome of psychodynamic psychotherapy for psychological disorders. Clinical Neuroscience Research. 2005;4(5-6):367- 77. http://dx.doi.org/10.1016/j.cnr.2005.03.005

  24. Berg RC, Høie B. Effectiveness of psychotherapy for adults with depression: a systematic review of the best available evidence. Procedia - Social and Behavioral Sciences. 2010;5:2194-200. doi:10.1016/j. sbspro.2010.07.435.

  25. Miró MT, Feixas G. Aproximaciones a la psicoterapia. Primera edición. Barcelona, España: Paidós; 1993. p. 311.

  26. Bradshaw W, Roseborough D, Pahwa R, Jordan J. Evaluation of Psychodynamic Psychotherapy in a Community Mental Health Center. The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry. 2009;37(4):665-81.

  27. Keefe JR, McCarthy KS, Dinger U, Zilcha-Mano S, Barber JP. A meta-analytic review of psychodynamic therapies for anxiety disorders. Clin Psychol Rev. 2014 Jun;34(4):309-23. doi: 10.1016/j. cpr.2014.03.004.

  28. Jakobsen JC, Hansen JL, Simonsen E, Gluud C. The effect of adding psychodynamic therapy to antidepressants in patients with major depressive disorder. A systematic review of randomized clinical trials with meta-analyses and trial sequential analyses. Journal of Affective Disorders. 2012;137(1-3):4-14.

  29. Steinert C, Hofmann M, Kruse J, Leichsenring F. Relapse rates after psychotherapy for depression - stable long-term effects? A meta-analysis. Journal of Affective Disorders. 2014;168:107-18.

  30. Hoencamp E, Haffmans PM, Duivenvoorden HJ. Predictability of dropout in unipolar depressed outpatients. Eur Psychiatry. 1998;13(2):63-6. doi: 10.1016/S0924-9338(98)80020-5.

  31. Farrell NR, Deacon BJ. The relative importance of relational and scientific characteristics of psychotherapy: Perceptions of community members vs. therapists. J Behav Ther Exp Psychiatry. 2016 Mar;50:171-7. doi: 10.1016/j.jbtep.2015.08.004.

  32. Voz Pro Salud Mental. Estudio: Costo Social de los Trastornos mentales. La Depresión en México causa pérdidas anuales de 9 mmdp por ausentismo laboral. Abril 12; 2012.

  33. Wang PS, Simon GE, Kessler RC. Making the business case for enhanced depression care: the National Institute of Mental Health-harvard Work Outcomes Research and Cost-effectiveness Study. J Occup Environ Med. 2008 Apr;50(4):468-75. doi: 10.1097/JOM.0b013e31816a8931.

  34. Williams CD, Schouten R. Assessment of occupational impairment and disability from depression. J Occup Environ Med. 2008 Apr;50(4):441-50. doi: 10.1097/ JOM.0b013e318169ccd0.

  35. Instituto Mexicano del Seguro Social. Dirección de Prestaciones Médicas. Norma que establece las disposiciones generales para la aplicación de los Grupos Relacionados con el Diagnóstico en el Instituto Mexicano del Seguro Social. México, Distrito Federal: IMSS; 28 de septiembre de 2012.

  36. Lara-Muñoz MC, Robles-García R, Orozco R, Real T, Chisholm D, Medina-Mora ME. Estudio de costo-efectividad del tratamiento de la depresión en México. Salud Ment. 2010; 33(4):301-8.




2020     |     www.medigraphic.com